The BSE MidCap and SmallCap indices, however, underperformed the benchmarks
Its revenue from operations rose by a massive 145 per cent to Rs 28,902 crore for the reporting quarter
Biotechnology major Biocon has reported a 35.39 per cent decline in its consolidated net profit at Rs 108.4 crore for the quarter ended June 30, 2021 mainly on account of its share of loss in associate startup entity Bicara Therapeutics Inc. The company had posted a net profit of Rs 167.8 crore for the corresponding period of the previous fiscal, Biocon said in a late night filing on Thursday. Consolidated revenue of the company stood at Rs 1,807.8 crore for the quarter under consideration. It was Rs 1,712.1 crore for the same period a year ago, it added. "Consolidated revenues, at Rs 1,808 crore, saw a muted growth on account of COVID-related operational challenges at Biocon's API facilities, both in Bengaluru and Hyderabad," Biocon Executive Chairperson Kiran Mazumdar-Shaw said. Q1FY22 P&L was also impacted by a share of loss in its Boston-based associate start-up entity, Bicara Therapeutics Inc, she added. "The outlook for the rest of the year is promising with several drug ...
Mphasis won a total contract value (TCV) of $505 million in Direct business during the quarter, the highest ever in the history of the company
ICICI Bank Q1 preview: Analysts, across-the-board, remain bullish on the lender's bottom line figure and expect the profit after tax (PAT) to grow anywhere between 59 per cent to 95.5 per cent YoY
B2B e-commerce platform Indiamart Intermesh on Thursday posted a 19 per cent increase in consolidated net profit at Rs 88 crore for the quarter ended June 30, 2021.
IT firm Persistent Systems on Thursday reported a 68 per cent jump in consolidated net profit to Rs 151.2 crore for the April-June quarter of this year.
CanFin Homes on Thursday reported a nearly 17 per cent rise in its net profit at Rs 108.85 crore in the first quarter ended June 2021
Health, hygiene and nutrition grow 16% over pre-Covid levels
In constant currency, growth was 16.3 per cent on y-o-y basis, and 5.9 per cent on q-o-q basis
NII up 29% in Q1FY22 to Rs 1,406 crore; NIM rises to 3.05% from 2.43% a year ago
Covid-induced lockdown dents volumes, erodes margins
Gross direct premium income grew to Rs 3,733 crore in the reporting period, up 13 per cent over Rs 3,302 crore a year ago, which ICICI Lombard said was in line with the industry growth level.
Signs of a strong corporate earnings season lifted demand for risky equities
Earnings before interest, tax, depreciation and amortisation grew 8 per cent YoY to Rs 2,847 crore as against Rs 2,644 crore
Shares of Gland Pharma on Thursday jumped nearly 8 per cent after the company reported an 11.83 per cent increase in its consolidated net profit for the quarter ended June 30, 2021
The wholly owned subsidiary will leverage the growth opportunities in the evolving mobility space and will help the Company venture into the manufacturing of Electric and Hybrid vehicles
VNB growth was driven by a resilient business model, innovative product offerings and diversified distribution and product mix
ITC Q1 PREVIEW: During the quarter ended June, shareholders lost over 7 per cent of their wealth parked in ITC
Gland Pharma said the growth in revenue was contributed from a mix of launch of new products and volume growth in existing products